Pharma BD Deal Intelligence
Thermo Fisher paid $17.4B for PPD, one of the world's largest CROs, to create a fully integrated clinical development services offering. The deal added 30,000+ employees and trial management from Phase I through submission—a single-vendor play from reagent supply to regulatory.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Thermo Fisher completes $17.4 billion acquisition of PPD, a leading clinical research organization with more than 26,000 colleagues operating in nearly…
Thermo Fisher acquires clinical research services provider PPD for $17.4 billion, expanding its position in the $50 billion clinical research services industry.
Full year 2025 revenue grew 4% to $44.56 billion; PPD remains a Thermo Fisher industry-leading brand (no divestiture), confirming the acquisition thesis…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Thermo Fisher Scientific acquired PPD, a leading clinical research organization, for $47.50 per share in cash (approximately $17.4 billion enterprise value). The acquisition expanded Thermo Fisher's clinical research services capabilities.
$50.0B Global Market · $50B Total Addressable Market
Clinical research organizations provide outsourced pharmaceutical development services including clinical trial management, regulatory affairs, biostatistics, and pharmacovigilance. The CRO industry supports the growing complexity and cost of drug development across all therapeutic areas.
At deal time, the CRO market was consolidating rapidly with IQVIA, LabCorp/Covance, and ICON/PRA as major competitors. PPD was the fifth-largest CRO globally with $4.7B in 2020 revenue, and the acquisition made Thermo Fisher a top-3 player in clinical research services.
Thermo Fisher announces acquisition of PPD, a leading CRO, to add clinical research services.
Thermo Fisher acquires PPD at $47.50/share plus $3.5B net debt, creating integrated clinical research offering.
PPD contributes $7B+ revenue and >$2.00 adj. EPS in 2022, exceeding $6.5B revenue and $1.50 EPS targets.
On track for $125M total synergies by year 3: $75M cost + $50M revenue synergies from cross-selling.
PPD clinical research grows above Thermo Fisher 7% core organic growth rate. Integration gone smoothly.
PPD exceeded revenue and EPS projections in first full year. Integration smooth. CRO business grows above company average.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / PPD Inc. (this deal) | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2021 deals · Thermo Fisher Scientific Inc. deals · Multiple (undisclosed) deals